These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35959620)

  • 21. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.
    Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI
    Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer progression and substance P.
    Coveñas R; Muñoz M
    Histol Histopathol; 2014 Jul; 29(7):881-90. PubMed ID: 24535838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting.
    Li Q; Wu Y; Wang W; Deng S; Jiang C; Chen F; Zhao J; Li H; Bai X; Hou J; Da L; Zhao L; Gao J; Jin G
    Curr Probl Cancer; 2019 Dec; 43(6):100462. PubMed ID: 30709557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.
    Muñoz M; Coveñas R
    Saudi J Gastroenterol; 2016; 22(4):260-8. PubMed ID: 27488320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
    Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
    J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.
    Navari RM
    Cancer Invest; 2004; 22(4):569-76. PubMed ID: 15565815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines.
    Muñoz M; Rosso M; Coveñas R
    Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
    Kast RE
    J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro.
    Wang X; Douglas SD; Lai JP; Tuluc F; Tebas P; Ho WZ
    J Neuroimmune Pharmacol; 2007 Mar; 2(1):42-8. PubMed ID: 18040825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages.
    Zhao XN; Bai ZZ; Li CH; Sheng CL; Li HY
    Drug Des Devel Ther; 2020; 14():1943-1952. PubMed ID: 32546961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.
    Wu H; Cheng X; Huang F; Shao G; Meng Y; Wang L; Wang T; Jia X; Yang T; Wang X; Fu C
    Drug Des Devel Ther; 2020; 14():2413-2422. PubMed ID: 32606608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
    Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
    Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation.
    Cao X; Yang Y; Zhou W; Wang Y; Wang X; Ge X; Wang F; Zhou F; Deng X; Miao L
    BMC Cancer; 2023 May; 23(1):471. PubMed ID: 37221457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
    Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy.
    Jordan K; Kinitz I; Voigt W; Behlendorf T; Wolf HH; Schmoll HJ
    Eur J Cancer; 2009 May; 45(7):1184-1187. PubMed ID: 19135359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
    Muñoz M; Rosso M; Coveñas R
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Efficacy of Aprepitant in Patients with Gynecological Cancer after Chemotherapy Using Paclitaxel and Carboplatin.
    Maehara M; Ueda T; Miyahara D; Takahashi Y; Miyata K; Nam SO; Katsuda T; Kondo H; Miyamoto S
    Anticancer Res; 2015 Aug; 35(8):4527-34. PubMed ID: 26168497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1977-85. PubMed ID: 18042005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.
    Morita M; Kishi S; Ookura M; Matsuda Y; Tai K; Yamauchi T; Ueda T
    Curr Probl Cancer; 2017; 41(6):419-425. PubMed ID: 29061362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
    Muñoz M; Martinez-Armesto J; Coveñas R
    Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.